Bristol-Myers Squibb and ZAI Lab Enter Licensing Agreement to Develop, Manufacture and Commercialize Brivanib in China SHANGHAI) – Bristol-Myers Squibb Company (NYSE: BMY) and ZAI Lab Limited (ZAI Lab), a le

Source URL: www.zailaboratory.com

• Medicine
• Clinical medicine
• Health
• Bristol-Myers Squibb
• Hepatology
• Infectious causes of cancer
• RTT
• Brivanib alaninate
• Indoles
• Hepatocellular carcinoma
• Liver cancer
• Hepatitis